- Home
- BZUN vs MOLN Comparison
BZUN vs MOLN Comparison
Compare BZUN & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZUN
- MOLN
- Stock Information
- Founded
- BZUN 2007
- MOLN 2004
- Country
- BZUN China
- MOLN Switzerland
- Employees
- BZUN N/A
- MOLN N/A
- Industry
- BZUN Catalog/Specialty Distribution
- MOLN
- Sector
- BZUN Consumer Discretionary
- MOLN
- Exchange
- BZUN Nasdaq
- MOLN Nasdaq
- Market Cap
- BZUN 188.7M
- MOLN 195.4M
- IPO Year
- BZUN N/A
- MOLN 2021
- Fundamental
- Price
- BZUN $2.88
- MOLN $5.56
- Analyst Decision
- BZUN Strong Buy
- MOLN
- Analyst Count
- BZUN 3
- MOLN 0
- Target Price
- BZUN $3.20
- MOLN N/A
- AVG Volume (30 Days)
- BZUN 475.0K
- MOLN 7.1K
- Earning Date
- BZUN 11-21-2024
- MOLN 03-13-2025
- Dividend Yield
- BZUN N/A
- MOLN N/A
- EPS Growth
- BZUN N/A
- MOLN N/A
- EPS
- BZUN N/A
- MOLN N/A
- Revenue
- BZUN $1,312,737,613.00
- MOLN $7,105,397.00
- Revenue This Year
- BZUN $8.16
- MOLN N/A
- Revenue Next Year
- BZUN $4.71
- MOLN $29.41
- P/E Ratio
- BZUN N/A
- MOLN N/A
- Revenue Growth
- BZUN 7.26
- MOLN N/A
- 52 Week Low
- BZUN $1.92
- MOLN $3.32
- 52 Week High
- BZUN $4.38
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- BZUN 50.72
- MOLN 53.39
- Support Level
- BZUN $2.75
- MOLN $4.98
- Resistance Level
- BZUN $2.88
- MOLN $5.91
- Average True Range (ATR)
- BZUN 0.15
- MOLN 0.27
- MACD
- BZUN -0.02
- MOLN 0.08
- Stochastic Oscillator
- BZUN 53.33
- MOLN 69.45
About BZUN Baozun Inc.
Baozun Inc is an e-commerce service partner that helps brands execute their e-commerce strategies in China by selling their goods directly to customers online or by providing services to assist with their e-commerce operations. Its integrated end-to-end e-commerce service capabilities, omni-channel expertise, and technology-driven solutions. Company have two operating segments namely E-Commerce (including BEC and BZI) and Brand Management (BBM).
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.